ClinicalTrials.gg
RecruitingNCT07387328Vest-PUpdated Jun 3, 2026

Validation of New sEMG Electrode Placement Guidelines for the Triceps Surae in Post-stroke Individuals

An observational study in Stroke, sponsored by University Hospital, Ghent. Recruiting at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-03.

Sponsored by University Hospital, Ghent · Observational

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
20
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Stroke by University Hospital, Ghent — 9 open to participants now, 9 under way, none of them phase 3. Stroke · University Hospital, Ghent.

Started
2026
with 1 other
Observational
5 of 18
3 open now
Registered
17th of 18
by date

Among the 18 studies in Stroke by University Hospital, Ghent, this one is one of 2 that started in 2026, is one of 5 observational ones, and was the 17th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

9 of the 18 studies in Stroke by University Hospital, Ghent are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Stroke by University Hospital, Ghent, or all of them as a file.
02

Study summary

Background and rationale:

Surface electromyography (EMG) is a non-invasive method to measure muscle activity, among others in people after a stroke during gait analysis. Measurement quality is strongly influenced by electrode placement. However, the commonly used SENIAM guidelines do not take individual variations in muscle morphology into account, which can lead to inaccurate measurements. In previous research demonstrated that the standard placement on the triceps surae (medial and lateral gastrocnemius and soleus) was suboptimal at the group level and sometimes even problematic at the individual level. Therefore, new placement guidelines (EPICA guidelines, Electrode Placement for Individual Calf Anatomy) were developed, which are currently being tested in healthy individuals.

Method:

In this project aims to validate these newly developed guidelines in people after a stroke who exhibit atrophy of their calf muscles. For each participant, electrode positions on the hemiplegic side will be determined according to our guidelines while the participant is lying prone. Circular stickers will be used instead of actual EMG electrodes and will be placed according to the EPICA guidelines as well as according to the SENIAM guidelines. Subsequently, the muscle borders of the triceps surae will be identified on the participant's leg using 2D ultrasound. Afterwards, the distance between the electrodes and the surrounding muscle borders will be measured to map electrode placement on the muscle in order to validate the guidelines.

In the second part of this study, 3D ultrasound recordings will be made of the soleus, medial gastrocnemius, and lateral gastrocnemius with the electrodes (stickers) on these muscles, so that during image processing, electrode positions can be visualized relative to the entire muscle, including along the depth axis. In addition, participants who can safely walk without an ankle-foot orthosis will be asked to walk a maximum of five times ten meters. Additionally, an ultrasound probe will be attached to the leg to investigate how the electrode position relates to the muscle-tendon junction during movement. Subsequently, actual electrodes will also be placed to record muscle activity during walking and heel raises.

Furthermore, all participants will be asked to do a heel raise to activate the calf muscles. As such, the quality of the EMG signals will be evaluated. Other measurements will included: Fugl-Meyer Assessment of the lower limb, measure passive ankle range of motion with a goniometer, and measure lower leg length with a tape measure. These will be used as descriptive parameters of our study population.

Patients will be asked on a voluntary basis to participate in a second, short measurement approximately two weeks after the first session. During this measurement, electrode placement will again be performed according to the EPICA guidelines. 3D ultrasound will again be used to calculate the distances between the electrodes and the muscle borders. This second measurement is necessary to investigate the test-retest reliability of the EPICA guidelines in people after a stroke.

03

Conditions studied

  • Stroke

Browse trials for

Keywords

  • Surface electromyography
  • guidelines
  • SENIAM
  • 3D freehand ultrasound
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Persons after stroke.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult individuals who have experienced a stroke (CVA or cerebrovascular accident).
  • Have no other neurological disorder.
  • Are able to lie in the prone position for approximately one and a half hours.
  • Are able to walk without shoes for the walking component (only applicable to participants who will perform walking). The use of an assistive device such as a walking stick (or similar) is permitted.

Exclusion criteria

Exclusion Criteria:

  • Presence of other neurological or orthopedic conditions that may influence the measurements and results (e.g., Parkinson's disease, peripheral neuropathy of the lower limbs, severe ankle osteoarthritis limiting range of motion, etc.).
  • Having undergone a surgical intervention on the hemiparetic lower leg (e.g., ankle joint arthrodesis, etc.).
  • Severe cognitive impairments that prevent understanding participation in the study (assessed using the AbilityQ).
05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
20 participants (estimated)
Target follow-up
1 Day
Patient registry
Yes

Groups and cohorts

  • Persons after stroke.
06

What researchers measure

Primary outcomes

  1. Electrode-muscle boundary distances for EPICA-electrodes

    These distances, measured with a tape measure, will be obtained between the EPICA electrode positions and the muscle boundaries as visualized using 2D ultrasound.

    Time frame: At study enrollment and a second time at least two weeks later.

  2. Electrode-muscle boundary distances for SENIAM-electrodes

    These distances, measured with a tape measure, will be obtained between the SENIAM electrode positions and the muscle boundaries as visualized using 2D ultrasound.

    Time frame: At study enrollment.

  3. Triceps surae muscle geometry

    Triceps surae muscle geometry will be measured using 3D freehand ultrasound.

    Time frame: At study enrollment.

  4. Muscle-tendon junction displacement of the lateral gastrocnemius during walking.

    This will be measured with dynamic 2D ultrasound.

    Time frame: At study enrollment.

  5. Muscle-tendon junction displacement of the lateral gastrocnemius during a heel raise.

    This will be measured using dynamic 2D ultrasound.

    Time frame: At study enrollment.

  6. Muscle-tendon junction displacement of the medial gastrocnemius during walking.

    This will be measured using dynamic 2D ultrasound.

    Time frame: At study enrollment.

  7. Muscle-tendon junction displacement of the medial gastrocnemius during a heel raise.

    This will be measured using dynamic 2D ultrasound.

    Time frame: At study enrollment.

  8. Quality features of the surface electromyography signals obtained from the EPICA electrodes during the dynamic tasks.

    Time frame: At study enrollment.

  9. Quality features of the surface electromyography signals obtained from the SENIAM electrodes during the dynamic tasks.

    Time frame: At study enrollment.

  10. Fugl-Meyer Assessment score of the paretic lower limb.

    Minumum score is 0 and maximum score is 34. A higher score involves a less impaired hemiparetic leg.

    Time frame: At study enrollment.

  11. Passive ankle range of motion.

    This will be measured using a manual goniometer.

    Time frame: At study enrollment.

  12. Surface electromyography amplitude during the dynamic tasks.

    Time frame: At study enrollment.

  13. Surface electromyography timing during the dynamic tasks.

    Time frame: At study enrollment.

  14. Spatiotemporal parameters derived from inertial measurement units

    Time frame: At study enrollment.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • De Vlieger D, Bosman L, Swinnen E, Besomi M, Aeles J. Assessment of common electrode placement methods for surface electromyography recordings of the triceps surae muscles. J Electromyogr Kinesiol. 2025 Dec;85:103080. doi: 10.1016/j.jelekin.2025.103080. Epub 2025 Oct 24. PubMed 41218536 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2026 (actual). Primary completion is estimated for Oct 2027, 18 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2026
First posted
Feb 4, 2026
StartActual
Apr 17, 2026
Primary completionEst.
Oct 31, 2027
CompletionEst.
Oct 31, 2027
Last update
Jun 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07387328
Collaborators
University Ghent, Vrije Universiteit Brussel, Research Foundation Flanders
Responsible party
Sponsor
First posted
Feb 4, 2026
Start date
Apr 17, 2026
Primary completion
Oct 31, 2027 (estimated)
Completion
Oct 31, 2027 (estimated)
Last update
Jun 3, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion